Stem-cell firm BioTime said this week that it will open a subsidiary in China called BioTime Asia to expand its stem cell therapeutics and research tools to the Asian market.
BioTime Asia will be based at the Nanshan Memorial Medical Institute, or NSMMI, and will clinically develop and market therapeutic stem cell products in China and market stem cell research products in China and other Asian countries (…)
We have been told for almost a decade that stem cells are the future of medicine: that these tiny clumps of tissue could become a biological “repair kit”, able to regenerate or heal almost any part of the body. But amid all the prophecies of patches for damaged hearts, new nerve cells for spinal injuries or stroke victims, and insulin-producing cells for diabetics, few people predicted that it would be British-based scientists who would be leading the way in mapping out this new terrain.
Writing in The Daily Telegraph last week, Professor Steve Jones bemoaned the failure of
In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues—mainly bone—proved quicker, more effective and less invasive than traditional bone regeneration treatments.
Researchers from the University of Michigan School of Dentistry and the Michigan Center for Oral Health Research partnered with Ann Arbor-based Aastrom Biosciences Inc. in the clinical trial, which involved 24 patients who required jawbone reconstruction after tooth removal.
Patients either received experimental tissue repair cells or traditional guided bone regeneration therapy. The tissue repair cells, called ixmyelocel-T, are under development at Aastrom, which is a U-M spinout company.
Sierra Fedelem may look like any other 20-month-old, but her parents are doing everything they can to make sure her life is just like that of any other healthy human being.
Stem cell research has stirred quite the controversy in the United States, and though the current administration’s recent policy reversal on the issue could open the markets to treatments and commercialization, it’s still an option unavailable for American patients, like Sierra, unless they’re willing to travel across the world.
“The first time the neurologist said, ‘No, you don’t realize it, she’s never going to be able to walk, talk and
Stem Cell Therapeutics Corp. is pleased to announce the U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company’s Phase IIb clinical trial treating acute ischemic stroke.
Dr. Alan Moore, President and CEO, commented as follows:
“We are very pleased that our series of collaborative meetings with the FDA has resulted in this positive development. We are expecting to receive written notification from the FDA in the near future